全文获取类型
收费全文 | 6553篇 |
免费 | 352篇 |
国内免费 | 28篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 168篇 |
妇产科学 | 92篇 |
基础医学 | 931篇 |
口腔科学 | 223篇 |
临床医学 | 426篇 |
内科学 | 1464篇 |
皮肤病学 | 213篇 |
神经病学 | 810篇 |
特种医学 | 172篇 |
外科学 | 553篇 |
综合类 | 29篇 |
现状与发展 | 1篇 |
预防医学 | 358篇 |
眼科学 | 272篇 |
药学 | 553篇 |
中国医学 | 16篇 |
肿瘤学 | 609篇 |
出版年
2024年 | 8篇 |
2023年 | 54篇 |
2022年 | 117篇 |
2021年 | 171篇 |
2020年 | 105篇 |
2019年 | 141篇 |
2018年 | 148篇 |
2017年 | 127篇 |
2016年 | 171篇 |
2015年 | 176篇 |
2014年 | 219篇 |
2013年 | 257篇 |
2012年 | 464篇 |
2011年 | 544篇 |
2010年 | 300篇 |
2009年 | 220篇 |
2008年 | 431篇 |
2007年 | 456篇 |
2006年 | 443篇 |
2005年 | 454篇 |
2004年 | 445篇 |
2003年 | 415篇 |
2002年 | 402篇 |
2001年 | 35篇 |
2000年 | 36篇 |
1999年 | 50篇 |
1998年 | 69篇 |
1997年 | 43篇 |
1996年 | 55篇 |
1995年 | 41篇 |
1994年 | 33篇 |
1993年 | 29篇 |
1992年 | 25篇 |
1991年 | 27篇 |
1990年 | 27篇 |
1989年 | 19篇 |
1988年 | 19篇 |
1987年 | 18篇 |
1986年 | 10篇 |
1985年 | 17篇 |
1984年 | 16篇 |
1983年 | 7篇 |
1982年 | 16篇 |
1981年 | 10篇 |
1980年 | 17篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1974年 | 5篇 |
1972年 | 11篇 |
排序方式: 共有6933条查询结果,搜索用时 10 毫秒
61.
62.
Kenji Nakahama Hiroyasu Kaneda Koichi Ogawa Yoshiya Matsumoto Yoko Tani Tomohiro Suzumura Shigeki Mitsuoka Tetsuya Watanabe Kazuhisa Asai Tomoya Kawaguchi 《Internal medicine (Tokyo, Japan)》2022,61(7):1039
A 68-year-old Japanese man was diagnosed with lung adenocarcinoma stage IVB. We introduced a first-line chemotherapy of four cycles of carboplatin and pemetrexed and pembrolizumab, followed by pemetrexed and pembrolizumab maintenance therapy. Approximately four months after anticancer therapy, a small nodule appeared in the right peripheral S3 lesion. After five months, the nodule was confirmed as a Mycobacterium tuberculosis (TB) nodule. We initiated anti-TB therapy without stopping pembrolizumab, and the right S3 nodule shrank immediately. This report supports the concurrent use of anti-TB treatment with an immune checkpoint inhibitor when the TB infection area is limited. 相似文献
63.
Onodera M Kawakami H Kuwatani M Kudo T Haba S Abe Y Kawahata S Eto K Nasu Y Tanaka E Hirano S Asaka M 《Surgical endoscopy》2012,26(6):1710-1717
Background
Endoscopic ultrasound (EUS)-guided drainage is widely used to manage pancreatic pseudocysts. Several studies have reported the use of EUS-guided drainage for pancreatic fistula and stasis of pancreatic juice caused by stricture of the pancreatic duct after pancreatic resection.Methods
At the authors’ hospital, 262 patients underwent surgery involving pancreatic resection from April 2005 to March 2010. In 90 of these patients (34%), a grade B or C postoperative pancreatic fistula developed that required additional treatment. The authors performed EUS-guided transmural drainage (EUS-TD) for six patients (2.1%) with a pancreatic fistula or dilation of the main pancreatic duct visible by EUS. Percutaneous drainage was provided for 18 patients (6.8%). The success rates for EUS-TD and percutaneous drainage were compared in a retrospective analysis.Results
In all six cases, EUS-TD was performed successfully without complications. Five of the six patients were successfully treated with only one trial of EUS-TD. The final technical success rate was 100% for both EUS-TD and percutaneous drainage. Both the short- and long-term clinical success rates for EUS-TD were 100% and those for percutaneous drainage were 61.1 and 83%, respectively. The differences in these rates were not significant (short-term success, P?=?0.091 vs. long-term success, P?=?0.403). However, the time to clinical success was significantly shorter with EUS-TD (5.8?days) than with percutaneous drainage (30.4?days; P?=?0.0013) in the current series.Conclusions
The EUS-TD approach appears to be a safe and technically feasible alternative to percutaneous drainage and may be considered as first-line therapy for pancreatic fistulas visible by EUS. 相似文献64.
Asako Kitahara Akinori Ebihara Shohei Obayashi Yukihiro Horio Yoshitaka Ono Tomohiro Yoshikawa Naoki Okada Jun Tanaka Hiroto Takiguchi Naoki Hayama Yoko Ito Tsuyoshi Oguma Ichiro Kuwahira Koichiro Asano 《Internal medicine (Tokyo, Japan)》2022,61(8):1219
A 44-year-old man developed coronavirus disease 2019 (COVID-19) pneumonia during immunochemotherapy consisting of carboplatin, paclitaxel, and pembrolizumab for non-small cell lung cancer. Low-grade fever, followed by mild hypoxemia, and febrile neutropenia, were observed, and granulocyte colony-stimulating factor (G-CSF) was administered until the recovery of neutropenia, when he developed a high fever, severe hypoxemia, and hypotension accompanied by consolidation in the bilateral lungs. His conditions promptly improved after treatment including hydrocortisone and the primary and metastatic tumors remained regressed for 10 months without further treatment. Post-COVID-19 organizing pneumonia during cancer immunochemotherapy can be aggravated by immune-checkpoint inhibitors and G-CSF. 相似文献
65.
Satoshi Okayama M.D. Yoko Dote M.D. Yukiji Takeda M.D. Shiro Uemura M.D. Shinichi Fujimoto M.D. Ph.D. Yoshihiko Saito M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2013,30(1):E13-E15
A 63‐year‐old man was referred to our hospital because of a cardiac tumor. Transthoracic echocardiography revealed a rough, mobile tumor in the dilated right atrium, and transesophageal echocardiography showed that the tumor consisted of small, botryoidal masses. Catheter‐based biopsy carried a high risk of embolism. Therefore, we used F‐18‐fluorodeoxyglucose positron emission tomography (FDG‐PET), which revealed an abnormal accumulation in the right cervical lymph nodes, as well as in the heart. We safely performed biopsy of the lymph nodes and diagnosed the patient with primary cardiac lymphoma. We concluded that echocardiography and FDG‐PET are useful for selecting an appropriate biopsy site in primary cardiac lymphoma. 相似文献
66.
67.
68.
Aki Masuzawa Chikako Kiyotani Tomoo Osumi Yoko Shioda Kazutoshi Iijima Osamu Tomita Kazuhiko Nakabayashi Keisuke Oboki Kazuki Yasuda Hiromi Sakamoto Hitoshi Ichikawa Kenichiro Hata Teruhiko Yoshida Kenji Matsumoto Nobutaka Kiyokawa Tetsuya Mori 《European journal of haematology》2014,92(3):263-267
In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2‐ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2‐ABL1 fusion exhibited a BCR‐ABL1+ ALL‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype‐based treatment stratification for patients with SNX2‐ABL1 fusion. 相似文献
69.
70.
Ken Fukunaga Yoshio Ohda Nobuyuki Hida Masaki Iimuro Yoko Yokoyama Koji Kamikozuru Kazuko Nagase Shiro Nakamura Hiroto Miwa Takayuki Matsumoto 《Journal of gastroenterology and hepatology》2012,27(12):1808-1815
Background and Aim: Topical mesalamine or corticosteroid has shown efficacy in patients with ulcerative proctitis, but patients often become refractory to these interventions. Xilei San is a herbal preparation with evidence of anti‐inflammatory effects. We evaluated the efficacy of topical Xilei San in ulcerative proctitis patients. Methods: In a double blind setting, 30 patients with intractable ulcerative proctitis despite ≥ 4 weeks of topical mesalamine or corticosteroid were randomly assigned to True (n = 15) and placebo (n = 15). Patients in True received suppository Xilei San (0.1 g/dose per day of Xilei San), the other 15 received placebo suppository. The initial efficacy was evaluated on day 14. Primary endpoint of the trial was avoiding relapse during 180 days, relapse meant recurrence of active disease. Riley's index was applied for endoscopic and histological evaluations, while patients' quality of life was evaluated by an inflammatory bowel disease questionnaire. Results: On day 14, the number of patients who achieved remission, clinical activity index ≤ 4 in True was significantly higher versus placebo (P < 0.04). Likewise, at day 180, an 81.8% of patients in True were without relapse versus 16.7% in placebo (P < 0.001). Further, significant endoscopic (P < 0.01), histological (P < 0.02) and inflammatory bowel disease questionnaire (P < 0.04) improvements were observed in True, but not in placebo. Conclusions: This is the first controlled investigation showing significant clinical and endoscopic efficacy for Xilei San in patients with intractable ulcerative proctitis. Topical Xilei San was well tolerated, and was without safety concerns. 相似文献